Dror Bashan, Protalix's President and Chief Executive Officer commented, 'We have three key initiatives as a management team which include improving our capital structure, pursuing strategic partnerships and alliances and actively moving our pipeline toward commercialization.' The Company also reported that it is actively pursuing potential partnering discussions for its other pipeline candidates, OPRX-106, an orally-delivered anti-inflammatory treatment, and alidornase alfa, a modified form of recombinant DNase (rhDNASE
), as well as partnerships with other company's compounds combined with Protalix's ProCellEx platform.
Data from 2005 from the Red Cross War Memorial Children's Hospital CF clinic cohort in Cape Town indicated that the median age of diagnosis and survival age during the preceding 33 years were 6 months and 19.8 years, respectively. Absence of newborn screening, limited access to sweat testing for diagnosis and restricted availability of expensive CF medications (such as inhaled rhDNAse
) or lung transplantation are barriers to improving CF survival in SA.